CoChat
Sign Up
Cited by 247Adrenal and Paraganglionic TumorsRenal cell carcinoma treatmentAdrenal Hormones and Disorders

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients

Crucitti, Francesco, Bellantone, Rocco, Ferrante, Angela, Boscherini, Mauro, Crucitti, Pierfilippo·1996·Surgery
DOI 10.1016/s0039-6060(96)80164-4
Open this paper in CoChat — free account

Abstract

Background Adrenal cortical carcinoma is an uncommon tumor with a poor prognosis. The low incidence of this tumor makes it difficult to achieve reliable data on clinical manifestations, natural history, and the impact of therapies. The purpose of this study was to evaluate such aspects in a large series.Methods A retrospective series of 129 cases (55 men and 74 women, mean age of 49 years) was collected from 18 surgical institutions. At the time of diagnosis 45.7% of patients had endocrine symptoms. One hundred twenty-four patients underwent surgery, which was considered curative in 91 cases and palliative in 33. Sixty-three patients had local disease, 48 had regional disease, and 43 had distant metastases.Results This study confirmed a higher incidence in the 40- to 50-year-old population with a female prevalence; hormonal hyperincretion was more common in women, but it was not caused by advanced disease. The overall 5-year survival rate was 35%. Tumor stage and curative resection affected prognosis significantly. The influence of gender, side, age, and hormonal function has not been confirmed. Adjuvant therapies were ineffective in prolonging survival. Reoperated patients experienced better survival (mean, 41.5 months) than nonreoperated cases (mean, 15.6 months).Conclusions The poor prognosis of adrenal cortical carcinoma may be improved by early diagnosis and complete resection. Radical surgery is the sole effective therapy, particularly in early stages. Surgical treatment of recurrence seems to improve survival and should be attempted systematically. Adjuvant therapies obtained contrasting results, and their role should be evaluated in prospective multicentric trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0039-6060(96)80164-4

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 66 references

Research works printed but not linked: 2

  1. Merrin, 1979, Treatment of genitourinary tumors with cisdichlorodiammineplatinum (II): experience in 250 patients, Cancer Treat Rep, 63, 1579
  2. Bukowski, 1990, Cisplatin (CDDP) and mitotane in metastatic adrenal carcinoma: a Southwestern Oncology Group study [Abstract], Proc Am Soc Clin Oncol, 9, 136

Cited by

Sorted by citations

Items 101–200 of 246

Related

See all

Metadata

Authors
Crucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P.
Affiliations
Università Cattolica del Sacro Cuore (IT)
Corresponding author
Ferrante, Angela
ORCID
Venue
Surgery
Publisher
Elsevier BV
Published
1996-02
Volume
119
Issue
2
Pages
161-170
ISSN
0039-6060 (ISSN-L)
DOI
10.1016/s0039-6060(96)80164-4
OpenAlex
W2095310757
Cited by
247
References
66
Citations by year
2026: 1 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 10 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 19 · 2014: 14 · 2013: 7 · 2012: 17
FWCI
3.74
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
adrenocortical carcinoma, prognosis, survival, adrenalectomy, curative resection, tumor stage, metastasis, adjuvant therapy, reoperation, endocrine symptoms, natural history (disease)
MeSH terms
Actuarial Analysis, Adolescent, Adrenal Cortex Neoplasms, Adrenalectomy, Adult, Age Factors, Aged, Aged, 80 and over, Child, Female, Humans, Italy, Male, Middle Aged, Neoplasm Staging, Palliative Care, Prognosis, Radiotherapy, Radiotherapy Dosage, Recurrence, Registries, Time Factors, Incidence, Survival Rate, Chemotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review